A total of 35 healthy adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, pre-screened to be receiving long term statin therapy of ≥ 6 months and negative for diabetes (defined as HbA1c <6.5%) will be enrolled upon written informed consent. They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)

Another 35 healthy non-diabetic adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, not receiving long-term statins will serve as controls will be enrolled upon written informed consent.
They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)

Yellow Fever Vaccine

Yellow Fever

They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)

Stamaril (live attenuated yellow fever vaccine)

SingHealth Investigational Medicine Unit

Yellow Fever Vaccine on Statin/ Non Statin Subjects

Using Systems Vaccinology to Elucidate the Effects of Anti-inflammatory Therapy on Immune Response After Vaccination With a Live Attenuated Vaccine

the difference in neutralizing antibody titer to YF17D at Day 28, as measured by plaque reduction neutralization test (PRNT)

viremia levels response in adult human volunteers on long term statins therapy compared to controls post-YF vaccination

To examine the Cd4+ and Cd8+ T cell response in adult human volunteers on long term statins therapy compared to controls post-YF vaccination

poliomyelitis/гојазност

Yellow Fever Vaccine on Statin/ Non Statin Subjects

Effectiveness of Trivalent Inactivated Influenza Maternal Vaccination Among Pregnant Women and Their Newborns in South Africa

Најкомплетнија база лековитог биља подржана науком